Neuroprotective effects of lithium in neuropsychiatric disorders

Neuroscience

• Neuroprotective Agent 100%
• Psychopathology 100%
• Cell Signaling 66%
• Protein Kinase B 66%
• Enzymes 66%
• Brain Disease 66%
• Multiple Sclerosis 33%
• Parkinson's Disease 33%
• Alzheimer's Disease 33%
• Amyotrophic Lateral Sclerosis 33%
• Bipolar Disorder 33%
• Brain-Derived Neurotrophic Factor 33%
• Central Nervous System 33%
• Neuroprotection 33%
• Glycogen Synthase Kinase 3 33%
• Autophagy 33%
• Mitochondrial Function 33%
• Nervous System Disorder 33%
• Fragile X Syndrome 33%
• Inositol 33%
• Huntington's Disease 33%
• Mood Stabilizer 33%
• Beta Arrestin 2 33%
• Cerebrovascular Accident 33%
• Phosphatase 33%
• Programmed Cell Death 33%
• Cellular Processes 33%

Keyphrases

• Lithium 100%
• Neuroprotective Effect 100%
• Brain Diseases 25%
• Multiple Sclerosis 12%
• Parkinson's Disease 12%
• Clinical Trials 12%
• Alzheimer's Disease 12%
• Amyotrophic Lateral Sclerosis 12%
• Bipolar Disorder 12%
• Phosphatase 12%
• Human Studies 12%
• Neuroprotection 12%
• Cell Signaling 12%
• Autophagy 12%
• Inducer 12%
• Mitochondrial Function 12%
• Huntington's Disease 12%
• Cellular Signaling 12%
• Neuroinflammation 12%
• Fragile X Syndrome 12%
• Neuroprotective Properties 12%
• Inositol Monophosphatase 12%
• Mood Stabilizers 12%
• Key Cells 12%
• Glycogen Synthase kinase-3β (GSK-3β) 12%
• Mitochondrial Apoptosis 12%
• β-arrestin2 12%
• Alzheime's Disease 12%
• Cellular Process 12%
• Neurodegenerative Disorders 12%
• Central Nervous System Diseases 12%